Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children

Clinical Infectious Diseases

Volumn 46, Issue 10, 2008, Pages 1601-1608

  Cressey, Tim R ^a,b,h,ar   Green, Hannah ^c,ar   Khoo, Saye ^d,ar   Treluyer, Jean Marc ^e   Compagnucci, Alexandra ^f,ar   Saidi, Yacine ^f   Lallemant, Marc ^a,b,h,ar   Gibb, Diana M ^c,ai,ar   Burger, David M ^g,ar   Aboulker, J P ^f,ar   Babiker, A ^c,ar   Blanche, S ^ar   Bohlin, A B ^ar   Butler, K ^ar   Castelli Gattinara, G ^s,ar   Clayden, P ^ar   Darbyshire, J H ^c,ar   Debre M ^ar   de Groot, R ^ar   della Negra, M ^ar   Duicelescu, D ^ar   Giaquinto, C ^q,ar   Grosch Worner I ^ar   Kind, C ^ar   Levy, J ^ar   Lyall, H ^ag,ah,ar   Marczynska, M ^u,ar   Mellado Pena M J ^ar   Nadal, D ^ac,ar   Niehues, T ^ar   Peckham, C ^ar   Ramos Amador, J T ^x,ar   Rosado, L ^ar   Rudin, C ^ar   Scherpbier, H J ^ar   Sharland, M ^ar   Stevanovic, M ^ar   Tovo, P A ^ar   Tudor Williams, G ^ag,ar   Valerius, N ^ar   Walker, A S ^c,ar   Wintergerst, U ^ar   Harper, L ^c,ar   Klein, N ^ai,ar   Mofenson, L ^i,ar   Moye, J ^i,ar   Saidi Y ^f,ar   Jacqz Aigrain, E ^ar   Treluyer J M ^ar   Clerici, M ^ar   De Rossi, A ^ar   Ngo Giang huong, N ^h,ar   Munoz Fernandez M A ^y,ar   Pillay, D ^am,ar   Hill, C ^ar   Lepage, P ^ar   Pozniak, A ^ar   Vella, S ^ar   Eliette, V ^f   Hadjou, G ^f   Leonardo S ^f   Pitrou, C ^f   Riault, Y ^f   Buck, L ^c   Farrelly, L ^c,ai   Johnson, D ^c   Taylor, C ^c   Chalermpantmetagul, S ^h   Peongjakta, R ^h   Chailert, S ^h   Fregonese, F ^h   Jourdain, G ^h   Butler, D ⁱ   Carlton, C ⁱ   Collins, D ⁱ   Kao, G ⁱ   Van Buskirk, S ⁱ   Watson, S ⁱ   Corradini, S ^j   Floret, D ^j   Laplace, J ^j   Monpoux, F ^k   Cottalorda, J ^k   Lefebvre, J C ^k   Mellul, S ^k   Boudjoudi, N ^l   Firtion, G ^l   Faye, A ^m   Beniken, D ^m   Damond, F ^m   Tricoire, J ⁿ   Krivine, A ^e   Chaix, M L ^o   Winter Gerst, U ^p   Notheis, G ^p   Strotmann, G ^p   Schlieben, S ^p   Rampon, O ^q   Zanchetta, M ^q   Rosso, R ^r   Repeto, E ^r   Vitale, F ^r   Martino, A ^s   Bernardi, S ^s   Mazza, A ^t   Rossetti, G ^t   Dobosz, S ^u   Oldakowska, A ^u   Popielska, J ^u   Kaflik, M ^u   Stanczak, J ^u   Stanczac, T ^u   Dyda, T ^u   Gonzalez Tome M I ^v   Delgado Garcia R ^v   Jose Mellado Pena M ^w   Martin Fontelos P ^w   Pineiro Perez R ^w   Alimenti, A ^w   Penin, M ^w   Gurbindo, D ^y   Navarro Gomez, M L ^y   Jimenez, J L ^y   Prieto, C ^y   de Jose Gomez M I ^z   Garcia Rodriguez M C ^z   Moreno Perez D ^aa   Nunez Cuadros E ^aa   Asensi Botet, F ^ab   Perez A ^ab   Perez Tamarit M D ^ab   Kalhert, C ^ac   Schupbach, J ^ad   Bunupuradah, T ^ae   Ananworanich, J ^ae   Phanuphak, P ^ae   Intasan, J ^ae   Ubolyam, S ^ae   Kanjanavanit, S ^af   Namwong, T ^af   Foster, C ^ag   Hamadache, D ^ag,ah   Campbell, S ^ag   Hanley, C ^ag   Walsh, C ^ag   Kaye, S ^ag   Seery, P ^ah   Novelli, V ^ai   Shingadia, D ^ai,ak   Flynn, J ^ai   Clapson, M ^ai   Jacobsen, M ^ai   McMaster, P ^aj   Hawkes, E ^aj   Liebeschuetz, S ^ak   Sodeinde, O ^ak   Wong, S ^ak   Walsh, S ^al   Heath, Y ^al   Weiner, L ^an   Famiglietti, M ^an   Rana, S ^ao   Yu, P ^ao   Roa, J ^ao   Puga, A ^ap   Haerry, A ^ap   Regazzi, M ^aq   Villani, S ^aq   Gibbons, S ^d   Jullien, V ^e   Rey, E ^e   Treluyer, J M ^e   Rodriguez Novoa S ^w   Tawon, Y ^a   more..

^a CHIANG MAI UNIVERSITY   (Thailand)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e HÔPITAL SAINT VINCENT DE PAUL   (France)

^f INSERM   (France)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h Program for HIV Prevention and Treatment   (Thailand)

ⁱ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^j EDOUARD HERRIOT HOSPITAL   (France)

^k CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^l Hôpital Cochin Port Royal ^*  (France)

^m HÔPITAL ROBERT DEBRÉ   (France)

ⁿ CHU PURPAN   (France)

^o HÔPITAL NECKER ENFANTS MALADES   (France)

^p Universitäts Kinderkliniken   (Germany)

^q UNIVERSITY OF PADOVA   (Italy)

^r UNIVERSITY OF GENOA   (Italy)

^s BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^t SANTA CHIARA HOSPITAL   (Italy)

^u SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

^v HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^w HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^x HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^y HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^z HOSPITAL INFANTIL LA PAZ   (Spain)

^aa HOSPITAL MATERNO INFANTIL   (Spain)

^ab HOSPITAL INFANTIL LA FE   (Spain)

^ac University Chidren s Hospital   (Switzerland)

^ad National Laboratory for Retrovirus   (Switzerland)

^ae AIDS Asia Regional Program   (Thailand)

^af NAKORNPING HOSPITAL   (Thailand)

^ag ST MARY S HOSPITAL   (United Kingdom)

^ah CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^ai GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^aj UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^ak NEWHAM UNIVERSITY HOSPITAL   (United Kingdom)

^al BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^am ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^an SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^ao HOWARD UNIVERSITY HOSPITAL   (United States)

^ap Children's Diagnostic and Treatment Center   (United States)

^aq FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^ar Istituto di Ricovero e Cura A Carattere Scientifico Policlinico San Matteo ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; BENZOXAZINE DERIVATIVE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVALUATION; FEMALE; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT PLANNING; VIRUS LOAD; ADOLESCENT; ANTIVIRAL RESISTANCE; BLOOD; CD4 CD8 RATIO; CHEMISTRY; CHILD; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MUTATION; PLASMA; TIME; TREATMENT WITHDRAWAL; VIROLOGY;

ADOLESCENT; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; NEVIRAPINE; PLASMA; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 43249121119     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587657     Document Type: Article

References (21)

1. Arnedo-Valero M, Garcia F, Gil C, et al. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Infect Dis. 2005;41:883–90.
2. Moore KH, Barrett JE, Shaw S, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 1999;13:2239–50.
3. Taylor S, Allen S, Fidler S, et al. Stop study: after discontinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer [abstract 131]; Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; San Francisco, California. 2004.
4. Kikaire B, Khoo S, Walker AS, et al. Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. AIDS. 2007;21:733–7.
5. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;38:283–8.
6. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229–40.
7. McIntyre J, Martnson N, Investigators for the Trial 1413 et al. Addition of short course combivir (CBV) to single dose viramune (sdNVP) for prevention of mother-to-child transmission (MTCT) of HIV-1 can significantly decrease the subsequent development of maternal NNRTI-resistant virus; Program and abstracts of the 15th International AIDS Conference; Bangkok, Thailand. 2004.
8. Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1–infected patients: the MaxCmin1 Trial. J Infect Dis. 2003;188:635–42.
9. Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48:824–31.
10. [Accessed 27 March 2008];Stanford University HIV database. Available at: http://hivdb.stanford.edu.
11. [Accessed 27 March 2008];HIV French Resistance Web site. HIV-1 genotypic drug resistance interpretation’s algorithms. AC11 ANRS algorithm. Available at: http://www.hivfrenchresistance.org.
12. Tariq Sadiq S, Fredericks S, Khoo SH, Rice P, Holt DW. Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance. AIDS. 2005;19:1716–7.
13. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391–400.
14. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1–5.
15. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006;42:401–7.
16. Ellis GM, Mahalanabis M, Beck IA, et al. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol. 2004;42:3670–4.
17. Shi C, Eshleman SH, Jones D, et al. LigAmp for sensitive detection of single-nucleotide differences. Nature Methods. 2004;1:141–7.
18. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA. 2006;103:7094–9.
19. Yap SH, Sheen CW, Fahey J, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Medicine. 2007;4:e335.
20. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 2000;14:F111–5.
21. Eshleman SH, Church JD, Chen S, et al. Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D. J Acquir Immune Defic Syndr. 2006;42:518–21.